Company Profile

Abacus Bioscience Inc
Profile last edited on: 3/24/2023      CAGE: 8JP28      UEI: DXS6HM6CLDF5

Business Identifier: Immunotherapies for treatment of chronic infectious diseases and cancers.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

27213 Se 27th Street
Sammamish, WA 98075
   (206) 543-8706
Location: Single
Congr. District: 08
County: King

Public Profile

Describing what they do as expanding the Immunotherapy Frontier - developing novel treatments for cancer/antiviral diseases, Abacus Bioscience Inc is developing what is described as a new class of immunotherapy that unleashes the power of a novel CD180 platform technology. The firm's Antigen-Specific Immune Accelerants (ASIA) are described as potent, specific and durable with broad applications across infectious disease and oncology.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 NIH $398,040
Project Title: Development of Novel CD180-Based Cancer Immunotherapeutics

Key People / Management

  Alan Wahl -- Chief Executive Officer

  Edward Clark

  Che-Leung Law -- Chief Science Officer

  Craig W Philips -- Founder

Company News

There are no news available.